Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.37 |
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | ODC1 | P11926 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1868299 | 1.00 | GSR (0.45) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL530046 | 1.00 | GSR (0.45) | GSRDPP7DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL29243120 | 0.98 | GSR (0.44) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL1010091 | 0.82 | GSR (0.47) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL8778638 | 0.80 | GSR (0.45) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL8778639 | 0.80 | GSR (0.45) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL27263635 | 0.79 | GSR (0.48) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL1537223 | 0.79 | GSR (0.52) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL29075853 | 0.79 | GSR (0.52) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL997560 | 0.79 | GSR (0.52) | GSRDPP7DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112481337-B | High mannose glycoform content of regulatory ornithine metabolism to manipulate recombinant proteins | 美国安进公司 | 2024-06-25 | — | — | CN | claimed |
| CN-117915926-A | Serometabonomics associated with Chimeric Antigen Receptor (CAR) T cell therapy | 得克萨斯州大学系统董事会 | 2024-04-19 | — | — | CN | claimed |
| CN-117467776-A | Method for promoting arginine to improve pig intestinal stress by SLC7A7 transport protein | 山西农业大学 | 2024-01-30 | — | — | CN | claimed |
| CN-116806157-A | Linker-payload and conjugates thereof | 芬兰吉利科斯有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-115666642-A | Drug conjugates containing alpha-enolase antibodies and uses thereof | 上毅生物科技股份有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-114502195-A | Methods of treating cancer using TNFRSF25 antibodies | 派立卡恩治疗公司 | 2022-05-13 | — | — | CN | claimed |
| CN-113747947-A | Combination therapy | 沙塔克实验室有限公司 | 2021-12-03 | — | — | CN | claimed |
| CN-113382750-A | CDCP1 targeted therapy | 贝斯以色列女执事医疗中心 | 2021-09-10 | — | — | CN | claimed |
| CN-113201073-A | Bispecific EGFR/c-Met antibodies | 詹森生物科技公司 | 2021-08-03 | — | — | CN | claimed |
| CN-112218658-A | Use of caloric restriction mimetics for enhancing chemoimmunotherapy for cancer treatment | 国家健康科学研究所 | 2021-01-12 | — | — | CN | claimed |
| US-8633168-B2 | Inhibitors of S-adenosyl-L-methionine decarboxylase | GENZYME CORPORATION (US) | 2014-01-21 | — | — | US | claimed |
| US-20100261668-A1 | INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE | GENZYME CORPORATION | 2010-10-14 | — | — | US | claimed |
| WO-2008157438-A1 | INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE | GENZYME CORPORATION (US) | 2008-12-24 | — | — | WO | claimed |
| EP-0863990-B1 | USE OF ANTI-SENSE SEQUENCES TO INCREASE RESPONSIVENESS TO GENE AMPLIFICATION | INTERPHARM LAB LTD (IL) | 2002-08-28 | — | — | EP | claimed |
| EP-0863990-A1 | USE OF ANTI-SENSE SEQUENCES TO INCREASE RESPONSIVENESS TO GENE AMPLIFICATION | INTERPHARM LABORATORIES LTD. (IL) | 1998-09-16 | — | — | EP | claimed |
| WO-1997020055-A1 | USE OF ANTI-SENSE SEQUENCES TO INCREASE RESPONSIVENESS TO GENE AMPLIFICATION | INTERPHARM LABORATORIES LTD. (IL) | 1997-06-05 | — | — | WO | claimed |
| EP-0319206-A2 | Gene amplification | BERLEX LABORATORIES, INC. (US) | 1989-06-07 | — | — | EP | claimed |
| CN-121154608-A | Application of difluoromethyl ornithine in preparation of antitumor drugs | 山东科睿易晶生物技术有限公司 | 2025-12-19 | — | — | CN | disclosed |
| EP-0248217-A2 | Use of ornithine decarboxylase inhibitor for preparing a medicament for use in the treatment, in conjuction with LAK cells and interleukin-2, of tumors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-12-09 | — | — | EP | disclosed |
| EP-0162413-A2 | Polyamine for use as a medicine in the treatment of neoplasms | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261668-A1 | INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE | AMD1, MAT1A, AHCY | GSR 305/4885DPP7 2018/4885DPP4 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.